These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27238065)

  • 41. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and Treatment Outcomes of Persistent Negative Mood Among Children with Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior.
    Blader JC; Pliszka SR; Kafantaris V; Sauder C; Posner J; Foley CA; Carlson GA; Crowell JA; Margulies DM
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):164-73. PubMed ID: 26745211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics.
    Johnston C; Hommersen P; Seipp C
    Behav Ther; 2008 Mar; 39(1):22-32. PubMed ID: 18328867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
    Magalotti SR; Neudecker M; Zaraa SG; McVoy MK
    Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.
    Fernández-Mayoralas DM; Fernández-Jaén A; Muñoz-Jareño N; Calleja-Pérez B; Fernández-Perrone AL; Arribas SL
    Clin Neuropharmacol; 2012; 35(5):227-30. PubMed ID: 22935606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
    Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M
    Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
    Barzman DH; DelBello MP; Adler CM; Stanford KE; Strakowski SM
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):665-70. PubMed ID: 17201610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder.
    Goez H; Back-Bennet O; Zelnik N
    J Child Neurol; 2007 May; 22(5):538-42. PubMed ID: 17690058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J; Döpfner M; Lehmkuhl G; ; Uebel H; Schmeck K; Poustka F; Gerber WD; Günter M; Knölker U; Gehrke M; Hässler F; Resch F; Brünger M; Ose C; Fischer R
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
    Elbe D; Barr AM; Honer WG; Procyshyn RM
    J Psychiatry Neurosci; 2014 May; 39(3):E32-3. PubMed ID: 24758945
    [No Abstract]   [Full Text] [Related]  

  • 55. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
    Hazell PL; Stuart JE
    J Am Acad Child Adolesc Psychiatry; 2003 Aug; 42(8):886-94. PubMed ID: 12874489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
    Pozzi M; Pisano S; Bertella S; Capuano A; Rizzo R; Antoniazzi S; Auricchio F; Carnovale C; Cattaneo D; Ferrajolo C; Gentili M; Guastella G; Mani E; Rafaniello C; Riccio MP; Scuderi MG; Sperandeo S; Sportiello L; Villa L; Radice S; Clementi E; Rossi F; Pascotto A; Bernardini R; Molteni M; Bravaccio C
    J Clin Psychiatry; 2016 Dec; 77(12):e1601-e1609. PubMed ID: 27780333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial.
    Myers K; Vander Stoep A; Zhou C; McCarty CA; Katon W
    J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):263-74. PubMed ID: 25791143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Computer-Assisted Social Skills Training in Children With Disruptive Behavior Disorders: A Randomized Controlled Trial.
    Goertz-Dorten A; Dose C; Hofmann L; Katzmann J; Groth M; Detering K; Hellmann A; Stadler L; Braun B; Hellmich M; Doepfner M
    J Am Acad Child Adolesc Psychiatry; 2022 Nov; 61(11):1329-1340. PubMed ID: 35398192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.